ImmunityBio secures $100 million in financing with debt conversion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St climbs after US, Iran pause conflict; focus on Fed, earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices near one-week low after US, Iran pause fighting over weekend
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy P
March 31, 2026 7:30 AM EDTImmunityBio to receive $75 million in non-dilutive funding under existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital, bringing total committed capital to $375 million Simultaneously conversion of $25 million of the outstanding promissory note held by Nant Capital, an entity affiliated with Executive Chairman bolstering ImmunityBios balance sheet with reduction in the debt Proceeds strengthen ImmunityBios balance sheet and support global expansion following recent approvals, while advancing companys broader immunotherapy pipeline
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc.... More
